model,flat_path,key_cat,val_cat,ref_val,pred_val,val_match,sim,score_status,piece,norm_path,from_pred,in_ref,in_pred,type_mismatch,is_enum,sim_failed
Claude-4.5-Sonnet,protocolSection.identificationModule.nctId,TP,TP,NCT04435795,NCT04435795,True,1.0,exact,NCTId,protocolSection.identificationModule.nctId,False,True,True,False,False,False
Claude-4.5-Sonnet,protocolSection.identificationModule.briefTitle,TP,TP,Inhaled Ciclesonide for Outpatients With COVID19,Inhaled and Intranasal Ciclesonide for the Treatment of COVID-19 in Nonhospitalized Adults,True,0.96,success,BriefTitle,protocolSection.identificationModule.briefTitle,False,True,True,False,False,False
Claude-4.5-Sonnet,protocolSection.identificationModule.officialTitle,TP,TP,Ciclesonide Clinical Trial for COVID-19 Treatment,"Inhaled and Intranasal Ciclesonide for the Treatment of COVID-19 in Nonhospitalized Adults: A Randomised, Double Blind, Placebo Controlled Trial",True,0.9,success,OfficialTitle,protocolSection.identificationModule.officialTitle,False,True,True,False,False,False
Claude-4.5-Sonnet,protocolSection.descriptionModule.briefSummary,TP,TP,"The CONTAIN (CiclesOnide cliNical TriAl covId-19 treatmeNt) is a randomized control study of ciclesonide vs placebo for mild covid-19 disease. The need for potential therapy for COVID-19 patients is urgent. Ciclesonide has shown encouraging in vitro results, is easy to be used and is readily available. It has a low rate of side effects and few interactions with other drugs. It is unusual to use an inhaled steroid drug for COVID-19 but there has been new data suggesting steroids may have an antiviral effect in addition to an anti-inflammatory effect. Investigators propose to use inhaled and nasal ciclesonide to stop viral replication in the nose and airways. Investigators hope this will accelerate recovery from COVID-19 illness in individuals who are not admitted to hospital at time of diagnosis of COVID-19.","This randomised, double blind, placebo controlled trial evaluated whether inhaled and intranasal ciclesonide can reduce respiratory symptoms in adult outpatients with covid-19. Participants were adults aged 18 years and older with polymerase chain reaction confirmed covid-19, presenting with fever, cough, or dyspnoea. They were randomised to receive either inhaled ciclesonide (600 μg twice daily) and intranasal ciclesonide (200 μg daily) or metered dose inhaler and nasal saline placebos for 14 days. The primary outcome was symptom resolution at day 7. The study aimed to determine if early administration of ciclesonide, which has demonstrated in vitro antiviral activity against SARS-CoV-2 and known anti-inflammatory effects, could decrease symptom burden in adults presenting with prominent respiratory symptoms.",True,0.96,success,BriefSummary,protocolSection.descriptionModule.briefSummary,False,True,True,False,False,False
Claude-4.5-Sonnet,protocolSection.descriptionModule.detailedDescription,EV,EV,,"The Inhaled Ciclesonide for the Treatment of COVID-19 in Nonhospitalized Adults (CONTAIN) trial was a multicentre, randomised, double blind, placebo controlled trial conducted across three Canadian provinces (Quebec, Ontario, and British Columbia). Participants were recruited through social media, telephone contact of individuals who tested positive for SARS-CoV-2, virtual telehealth clinics, and regional health authority lists. Eligible participants were adults aged 18 years and older with polymerase chain reaction confirmed covid-19 at enrolment, presenting with at least one of the following respiratory symptoms: fever, cough (wet or dry), or shortness of breath (including dyspnoea, chest congestion, or chest tightness). Exclusion criteria included hospital admission, having only non-respiratory symptoms, or already being prescribed an inhaled steroid. Participants were randomised in a 1:1 ratio to receive either inhaled ciclesonide (600 μg twice daily) and intranasal ciclesonide (200 μg daily) or matching placebos (saline metered dose inhaler and intranasal saline) for 14 days. The study aimed to recruit participants within five to six days of symptom onset or positive polymerase chain reaction test result to ensure early treatment initiation. The primary outcome was the resolution of self-reported fever and all respiratory symptoms (cough or dyspnoea) at day 7 of treatment. Secondary outcomes included hospital admission or death with covid-19, symptom resolution at day 14, improvement in overall feeling, resolution of dyspnoea, improvement in cough, and improvement in sleep, anxiety, and dyspnoea as measured by PROMIS (patient reported outcomes measurement information system) questionnaires. Participants completed surveys on day 0 (day of treatment receipt) and on days 1, 3, 7, 10, and 14, with a follow-up survey on day 29. Adverse events were collected through open-ended questions and specific queries about common side effects. The trial was stopped early in June 2021 due to declining case numbers and increased vaccination rates in Canada, resulting in an inability to meet the intended sample size. The modified intention-to-treat population included 203 participants (105 in the ciclesonide group and 98 in the placebo group). The median age was 35 years, 54% were women, and the majority were young and healthy with a high burden of respiratory symptoms. The trial was designed to detect a 15% absolute risk increase in symptom resolution from a baseline of 65% to 80% by day 7.",,,,DetailedDescription,protocolSection.descriptionModule.detailedDescription,True,False,True,False,False,False
Claude-4.5-Sonnet,protocolSection.conditionsModule.conditions,TP,FP,['COVID 19'],"['COVID-19', 'SARS-CoV-2', 'Respiratory Symptoms', 'Cough', 'Dyspnoea', 'Fever']",False,0.0,disjoint,Condition,protocolSection.conditionsModule.conditions,False,True,True,False,False,False
Claude-4.5-Sonnet,protocolSection.conditionsModule.keywords,EV,EV,,"['Ciclesonide', 'Inhaled Corticosteroids', 'Intranasal Corticosteroids', 'COVID-19 Treatment', 'Outpatients', 'Respiratory Symptoms', 'Placebo Controlled Trial', 'SARS-CoV-2', 'Symptom Resolution', 'Antiviral Effect', 'Anti-inflammatory Effect']",,,,Keyword,protocolSection.conditionsModule.keywords,True,False,True,False,False,False
Claude-4.5-Sonnet,protocolSection.designModule.studyType,TP,TP,INTERVENTIONAL,INTERVENTIONAL,True,1.0,exact,StudyType,protocolSection.designModule.studyType,False,True,True,False,True,False
Claude-4.5-Sonnet,protocolSection.designModule.patientRegistry,EV,EV,,False,,,,PatientRegistry,protocolSection.designModule.patientRegistry,True,False,True,False,False,False
Claude-4.5-Sonnet,protocolSection.designModule.phases,TP,FP,"['PHASE2', 'PHASE3']",['PHASE3'],False,0.5,partial,Phase,protocolSection.designModule.phases,False,True,True,False,True,False
Claude-4.5-Sonnet,protocolSection.designModule.designInfo.allocation,TP,TP,RANDOMIZED,RANDOMIZED,True,1.0,exact,DesignAllocation,protocolSection.designModule.designInfo.allocation,False,True,True,False,True,False
Claude-4.5-Sonnet,protocolSection.designModule.designInfo.interventionModel,TP,FP,FACTORIAL,PARALLEL,False,0.6,success,DesignInterventionModel,protocolSection.designModule.designInfo.interventionModel,False,True,True,False,True,False
Claude-4.5-Sonnet,protocolSection.designModule.designInfo.interventionModelDescription,EV,EV,,Participants were randomised in a 1:1 ratio to receive either inhaled ciclesonide (600 μg twice daily) and intranasal ciclesonide (200 μg daily) or metered dose inhaler and nasal saline placebos for 14 days.,,,,DesignInterventionModelDescription,protocolSection.designModule.designInfo.interventionModelDescription,True,False,True,False,False,False
Claude-4.5-Sonnet,protocolSection.designModule.designInfo.maskingInfo.masking,TP,TP,TRIPLE,QUADRUPLE,True,0.7,success,DesignMasking,protocolSection.designModule.designInfo.maskingInfo.masking,False,True,True,False,True,False
Claude-4.5-Sonnet,protocolSection.designModule.designInfo.maskingInfo.maskingDescription,EV,EV,,"Investigators, participants, and statisticians were blinded to treatment allocation. The assignments were concealed from investigators and participants; only pharmacies and a central research assistant had access to the treatment allocation. Overall, blinding was well maintained.",,,,DesignMaskingDescription,protocolSection.designModule.designInfo.maskingInfo.maskingDescription,True,False,True,False,False,False
Claude-4.5-Sonnet,protocolSection.designModule.designInfo.maskingInfo.whoMasked,TP,TP,"['PARTICIPANT', 'CARE_PROVIDER', 'INVESTIGATOR']","['PARTICIPANT', 'CARE_PROVIDER', 'INVESTIGATOR', 'OUTCOMES_ASSESSOR']",True,1.0,superset,DesignWhoMasked,protocolSection.designModule.designInfo.maskingInfo.whoMasked,False,True,True,False,True,False
Claude-4.5-Sonnet,protocolSection.designModule.enrollmentInfo.count,TP,TP,215,203,True,0.9,success,EnrollmentCount,protocolSection.designModule.enrollmentInfo.count,False,True,True,False,False,False
Claude-4.5-Sonnet,protocolSection.armsInterventionsModule.interventions[3].type,EV,EV,,DRUG,,,,InterventionType,protocolSection.armsInterventionsModule.interventions.type,True,False,True,False,False,False
Claude-4.5-Sonnet,protocolSection.armsInterventionsModule.interventions[3].name,EV,EV,,Intranasal Saline Placebo,,,,InterventionName,protocolSection.armsInterventionsModule.interventions.name,True,False,True,False,False,False
Claude-4.5-Sonnet,protocolSection.armsInterventionsModule.interventions[3].description,EV,EV,,"Intranasal saline placebo administered daily for 14 days, matched in appearance and dosing schedule to intranasal ciclesonide.",,,,InterventionDescription,protocolSection.armsInterventionsModule.interventions.description,True,False,True,False,False,False
Claude-4.5-Sonnet,protocolSection.armsInterventionsModule.interventions[3].armGroupLabels,EV,EV,,['Placebo Group'],,,,InterventionArmGroupLabel,protocolSection.armsInterventionsModule.interventions.armGroupLabels,True,False,True,False,False,False
Claude-4.5-Sonnet,protocolSection.outcomesModule.secondaryOutcomes[10].measure,EV,EV,,Improvement in anxiety (PROMIS emotional distress anxiety score 7a),,,,SecondaryOutcomeMeasure,protocolSection.outcomesModule.secondaryOutcomes.measure,True,False,True,False,False,False
Claude-4.5-Sonnet,protocolSection.outcomesModule.secondaryOutcomes[7].measure,EV,EV,,Improvement in cough by day 14,,,,SecondaryOutcomeMeasure,protocolSection.outcomesModule.secondaryOutcomes.measure,True,False,True,False,False,False
Claude-4.5-Sonnet,protocolSection.outcomesModule.secondaryOutcomes[8].measure,EV,EV,,Improvement in shortness of breath (PROMIS dyspnoea score),,,,SecondaryOutcomeMeasure,protocolSection.outcomesModule.secondaryOutcomes.measure,True,False,True,False,False,False
Claude-4.5-Sonnet,protocolSection.outcomesModule.secondaryOutcomes[9].measure,EV,EV,,Improvement in sleep (PROMIS sleep disturbance score 4a),,,,SecondaryOutcomeMeasure,protocolSection.outcomesModule.secondaryOutcomes.measure,True,False,True,False,False,False
Claude-4.5-Sonnet,protocolSection.outcomesModule.secondaryOutcomes[10].description,EV,EV,,Change in anxiety as measured by the PROMIS emotional distress anxiety score 7a (with meaningful improvement defined as a ≥3 point change on the T score).,,,,SecondaryOutcomeDescription,protocolSection.outcomesModule.secondaryOutcomes.description,True,False,True,False,False,False
Claude-4.5-Sonnet,protocolSection.outcomesModule.secondaryOutcomes[7].description,EV,EV,,The proportion of participants with improvement in cough (defined as a 2 point decrease or a decrease to 0 on a visual analogue scale that ranged from 0 for no symptoms to 10 for severe symptoms) in those who had cough at baseline by day 14.,,,,SecondaryOutcomeDescription,protocolSection.outcomesModule.secondaryOutcomes.description,True,False,True,False,False,False
Claude-4.5-Sonnet,protocolSection.outcomesModule.secondaryOutcomes[8].description,EV,EV,,Change in shortness of breath as measured by the PROMIS (patient reported outcomes measurement information system) dyspnoea score (with meaningful improvement defined as a ≥3 point change on the T score).,,,,SecondaryOutcomeDescription,protocolSection.outcomesModule.secondaryOutcomes.description,True,False,True,False,False,False
Claude-4.5-Sonnet,protocolSection.outcomesModule.secondaryOutcomes[9].description,EV,EV,,Change in sleep as measured by the PROMIS sleep disturbance score 4a (with meaningful improvement defined as a ≥3 point change on the T score).,,,,SecondaryOutcomeDescription,protocolSection.outcomesModule.secondaryOutcomes.description,True,False,True,False,False,False
Claude-4.5-Sonnet,protocolSection.outcomesModule.secondaryOutcomes[10].timeFrame,EV,EV,,"Days 1, 3, 7, 10, and 14 after enrollment",,,,SecondaryOutcomeTimeFrame,protocolSection.outcomesModule.secondaryOutcomes.timeFrame,True,False,True,False,False,False
Claude-4.5-Sonnet,protocolSection.outcomesModule.secondaryOutcomes[7].timeFrame,EV,EV,,Day 14 after enrollment,,,,SecondaryOutcomeTimeFrame,protocolSection.outcomesModule.secondaryOutcomes.timeFrame,True,False,True,False,False,False
Claude-4.5-Sonnet,protocolSection.outcomesModule.secondaryOutcomes[8].timeFrame,EV,EV,,"Days 1, 3, 7, 10, and 14 after enrollment",,,,SecondaryOutcomeTimeFrame,protocolSection.outcomesModule.secondaryOutcomes.timeFrame,True,False,True,False,False,False
Claude-4.5-Sonnet,protocolSection.outcomesModule.secondaryOutcomes[9].timeFrame,EV,EV,,"Days 1, 3, 7, 10, and 14 after enrollment",,,,SecondaryOutcomeTimeFrame,protocolSection.outcomesModule.secondaryOutcomes.timeFrame,True,False,True,False,False,False
Claude-4.5-Sonnet,protocolSection.eligibilityModule.eligibilityCriteria,TP,TP,"Inclusion Criteria:

Symptomatic adult patients positive by PCR for COVID-19 within 5 days of enrollment with fever, cough, or shortness of breath. Provision of Informed Consent

At day 0, patients should be at home

Exclusion Criteria:

* Already on inhaled corticosteroid medication
* Currently using systemic steroids (oral or intravenous or intramuscular such as Prednisone) or use of steroids 7 days prior to enrolment
* Severely ill patients at enrollment (i.e., admitted to ICU at admission)
* Unable to self-administer the inhaler
* Known or suspected pregnancy and breastfeeding
* Known allergy to study medication or its components (non-medicinal ingredients; including lactose allergy (type I))
* Patients with untreated fungal, bacterial, or tubercular infections of the respiratory tract
* Current hospitalization
* Current use of oxygen at home or in the hospital","Inclusion Criteria:
- Adults aged 18 years and older
- Polymerase chain reaction (PCR) confirmed covid-19 (SARS-CoV-2)
- At least one of the following symptoms: fever, cough (wet or dry), or shortness of breath (including dyspnoea, chest congestion, or chest tightness)
- Symptom onset within 5 days of enrolment (extended to 6 days if same-day shipping available)
- Able to provide online consent

Exclusion Criteria:
- Admitted to hospital
- Only non-respiratory symptoms (e.g., nasal congestion, myalgias, gastrointestinal symptoms)
- Already prescribed an inhaled steroid
- Vaccinated against COVID-19 (excluded from January 28, 2021 onwards)",True,0.78,success,EligibilityCriteria,protocolSection.eligibilityModule.eligibilityCriteria,False,True,True,False,False,False
Claude-4.5-Sonnet,protocolSection.eligibilityModule.healthyVolunteers,TP,TP,False,False,True,1.0,exact,HealthyVolunteers,protocolSection.eligibilityModule.healthyVolunteers,False,True,True,False,False,False
Claude-4.5-Sonnet,protocolSection.eligibilityModule.sex,TP,TP,ALL,ALL,True,1.0,exact,Sex,protocolSection.eligibilityModule.sex,False,True,True,False,True,False
Claude-4.5-Sonnet,protocolSection.eligibilityModule.minimumAge,TP,TP,18 Years,18 Years,True,1.0,exact,MinimumAge,protocolSection.eligibilityModule.minimumAge,False,True,True,False,False,False
Claude-4.5-Sonnet,protocolSection.eligibilityModule.maximumAge,EV,EV,,N/A,,,,MaximumAge,protocolSection.eligibilityModule.maximumAge,True,False,True,False,False,False
Claude-4.5-Sonnet,protocolSection.eligibilityModule.stdAges,TP,TP,"['ADULT', 'OLDER_ADULT']","['ADULT', 'OLDER_ADULT']",True,1.0,exact,StdAge,protocolSection.eligibilityModule.stdAges,False,True,True,False,True,False
